Diabetes News and Research

Latest Diabetes News and Research

Eisai to commercialize lorcaserin for obesity and weight management in U.S.

Arena Pharmaceuticals, Inc. today announced that Eisai Inc. will market lorcaserin for obesity and weight management in the United States following U.S. Food and Drug Administration (FDA) approval under the terms of a marketing and supply agreement between Arena Pharmaceuticals GmbH, a wholly owned subsidiary of Arena Pharmaceuticals, Inc., and Eisai. Lorcaserin, which Arena discovered and has developed for weight management, is intended for obese patients as well as overweight patients who have at least one weight-related co-morbid condition.

1 Jul 2010

Eisai signs agreement with Arena Pharmaceuticals GmbH to commercialize lorcaserin

Eisai Inc., the U.S. pharmaceutical operation of Tokyo-based Eisai Co., Ltd., announced today that it has entered into an agreement with Arena Pharmaceuticals GmbH, a wholly owned subsidiary of Arena Pharmaceuticals, Inc., for exclusive U.S. rights to commercialize lorcaserin, a drug candidate for potential use in the treatment of obesity, including weight loss, for patients who are obese (Body Mass Index or BMI ≥ 30) or overweight (BMI ≥ 27) with at least one weight-related co-morbid condition.

1 Jul 2010

Researchers report no increased rate of heart attack in patients taking rosiglitazone

The diabetes drug rosiglitazone has been under intense scrutiny since a 2007 study in the New England Journal of Medicine looked at more than 40 clinical trials and linked the drug's use with increased risk of heart attack and death from heart disease.

1 Jul 2010

Sepracor announces preliminary results from OMNARIS HFA Phase III study for seasonal allergic rhinitis

Sepracor Inc. announced today the preliminary results of a large-scale, 671-patient Phase III study of OMNARIS® (ciclesonide) HFA, an aerosol nasal formulation of ciclesonide, for the treatment of seasonal allergic rhinitis (SAR) in adult and adolescent patients. In this study, OMNARIS HFA met its primary efficacy endpoint by demonstrating a statistically significant reduction versus placebo in the reflective total nasal symptom score averaged over a two-week treatment period.

1 Jul 2010

BIDMC physician-scientist receives Young Investigator Award to research on prostate cancer

Akash Patnaik, MD, PhD, a physician-scientist in the Hematology/Oncology Divison at Beth Israel Deaconess Medical Center and Instructor of Medicine at Harvard Medical School has received a Young Investigator Award from The Prostate Cancer Foundation. The three-year $225,000 award, one of 21 made to young scientists from across the U.S. and Canada, is designed to encourage the most innovative minds in cancer research to focus their careers on prostate cancer.

1 Jul 2010

Biospherics acquires worldwide patent rights to Dtagatose from UKRF

Spherix Incorporated, an innovator in biotechnology for therapy in diabetes, metabolic syndrome, and atherosclerosis; and providers of technical and regulatory consulting services to food, supplement, biotechnology and pharmaceutical companies, today announced that its wholly-owned subsidiary, Biospherics Incorporated, has signed a license agreement with the University of Kentucky Research Foundation (UKRF).

1 Jul 2010

XOMA reaches enrollment goal of 325 patients for Phase 2b clinical trial of XOMA 052

XOMA Ltd., a leader in the discovery and development of therapeutic antibodies, announced that it has reached the enrollment goal of 325 patients for its Phase 2b dose-ranging clinical trial of XOMA 052, and that it expects patient enrollment to close in July 2010, with top-line results available in the first quarter of 2011. XOMA 052 is a therapeutic antibody candidate that inhibits the pro-inflammatory cytokine interleukin-1 beta (IL-1 beta) which drives the inflammatory cause of Type 2 diabetes.

1 Jul 2010

Roche, IBM announce agreement to develop nanopore-based sequencer for decoding human DNA

Roche and IBM announced today an agreement to develop a nanopore-based sequencer that will directly read and decode human DNA quickly and efficiently. Focused on advancing IBM's recently published "DNA Transistor" technology, the collaboration will take advantage of IBM's leadership in microelectronics, information technology and computational biology and Roche's expertise in medical diagnostics and genome sequencing.

1 Jul 2010

Prasco commences shipments of generic prescription ZEGERID Capsules

Santarus, Inc., a specialty biopharmaceutical company, today announced that pursuant to its distribution and supply agreement with Prasco, LLC, Prasco is commencing shipments of an authorized generic of prescription ZEGERID® (omeprazole/ sodium bicarbonate) Capsules in 20 mg and 40 mg dosage strengths in the U.S. under the Prasco label. ZEGERID is an immediate-release proton pump inhibitor (PPI) approved as a prescription product in the U.S. for the treatment of certain upper gastrointestinal diseases and disorders.

1 Jul 2010

GSD signs agreement with Axis-Shield to distribute its proprietary assays in the U.S. Market

Gold Standard Diagnostics, Inc. a leading supplier of products and services to the medical diagnostic industry today announced the execution of an agreement with Axis-Shield to distribute their proprietary assays in the U.S. Market. Axis-Shield owns a number of patents in the areas of cardiovascular and neurodegenerative diseases, rheumatoid arthritis, diabetes and more recently, sepsis. GSD will initially focus on distribution of Homocysteine, but also gains access to distribute Axis-Shield's other key products such as Anti-CCP.

1 Jul 2010

Fero Industries closes acquisition of rights related to production, marketing and distribution of Sucanon

Fero Industries, Inc. is pleased to announce that it has closed the acquisition of certain intellectual property and other associated rights related to the production, marketing, and distribution of Sucanon, a treatment for Type II diabetes.

1 Jul 2010

Transition commences dosing in TT-301 Phase 1 clinical study for rheumatoid arthritis, ICH, TBI

Transition Therapeutics Inc. announced today that the first patient has been dosed with drug candidate TT-301 in a Phase 1 clinical study. TT-301 is a small molecule compound that has demonstrated efficacy in preclinical models of rheumatoid arthritis, intracerebral haemorrhage and traumatic brain injury.

30 Jun 2010

Blue Shield of California offers SilverSneakers Fitness Program to Medicare Supplement Plan subscribers

Blue Shield of California is now offering the Healthways SilverSneakers® Fitness Program to subscribers of Blue Shield Medicare Supplement Plans throughout California. SilverSneakers, the nation's leading social support and exercise program designed to keep seniors healthy, has been a popular benefit with California Medicare HMOs, but Blue Shield is one of the few health plans in the state to offer the benefit as part of its Medicare Supplement plans as well.

30 Jun 2010

Excellence in Paediatrics to be held in London, from 2 - 4 December 2010

Experts from all over the world will be converging on the Park Plaza Hotel in Westminster, London, from 2 - 4 December 2010 for Excellence in Paediatrics, which promises cutting edge topics by outstanding speakers.

30 Jun 2010

Sensor integrated insulin pump for better blood sugar control

Adding a continuous blood sugar level sensor to an insulin pump helps patients with type 1 diabetes achieve better blood sugar control compared to the common standard of care, multiple daily insulin injections, concludes a study published on-line today in the New England Journal of Medicine.

30 Jun 2010

Medtronic's sensor-augmented insulin pump therapy provides superior glucose control, confirms STAR 3 study

In the longest and largest randomized, controlled study of sensor-augmented insulin pump therapy in type 1 diabetes, adult and pediatric patients using the Medtronic MiniMed Paradigm® REAL-Time System achieved better glucose control without an increase in hypoglycemia compared to multiple daily insulin injections (MDI), the most common approach to care today.

30 Jun 2010

European Congress of Nephrology unveils results of various clinical trials

The 47th ERA-EDTA/DGfN congress in Munich has been the setting for a wide range of new clinical data. The results of the following clinical trials were presented at "Late-Breaking Clinical Trials Sessions."

30 Jun 2010

Striking disparities persist; obesity rates highest among Blacks and Latinos

Adult obesity rates increased in 28 states in the past year, and declined only in the District of Columbia, according to F as in Fat: How Obesity Threatens America's Future 2010, a report from the Trust for America's Health and the Robert Wood Johnson Foundation.

30 Jun 2010

Study: Near-normal glucose control does not delay risk of organ damage in diabetes patients

In people with longstanding type 2 diabetes who are at high risk for heart attack and stroke, lowering blood sugar to near-normal levels did not delay the combined risk of diabetic damage to kidneys, eyes, or nerves, but did delay several other signs of diabetic damage, a study has found. The intensive glucose treatment was compared with standard glucose control.

30 Jun 2010

Study highlights importance of individualized, patient-centered therapies

In an analysis from the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial, one of the largest studies of its kind to determine whether intensive blood glucose (sugar) control worked better than standard blood sugar control among diabetics, results show that the benefits of intensive therapy need to be balanced against the increase in total and cardiovascular disease-related death, increased weight gain, and high risk for severe low blood sugar.

30 Jun 2010

Diabetes News and Research

Latest Diabetes News and Research

Eisai to commercialize lorcaserin for obesity and weight management in U.S.

Eisai signs agreement with Arena Pharmaceuticals GmbH to commercialize lorcaserin

Researchers report no increased rate of heart attack in patients taking rosiglitazone

Sepracor announces preliminary results from OMNARIS HFA Phase III study for seasonal allergic rhinitis

BIDMC physician-scientist receives Young Investigator Award to research on prostate cancer

Biospherics acquires worldwide patent rights to Dtagatose from UKRF

XOMA reaches enrollment goal of 325 patients for Phase 2b clinical trial of XOMA 052

Roche, IBM announce agreement to develop nanopore-based sequencer for decoding human DNA

Prasco commences shipments of generic prescription ZEGERID Capsules

GSD signs agreement with Axis-Shield to distribute its proprietary assays in the U.S. Market

Fero Industries closes acquisition of rights related to production, marketing and distribution of Sucanon

Transition commences dosing in TT-301 Phase 1 clinical study for rheumatoid arthritis, ICH, TBI

Blue Shield of California offers SilverSneakers Fitness Program to Medicare Supplement Plan subscribers

Excellence in Paediatrics to be held in London, from 2 - 4 December 2010

Sensor integrated insulin pump for better blood sugar control

Medtronic's sensor-augmented insulin pump therapy provides superior glucose control, confirms STAR 3 study

European Congress of Nephrology unveils results of various clinical trials

Striking disparities persist; obesity rates highest among Blacks and Latinos

Study: Near-normal glucose control does not delay risk of organ damage in diabetes patients

Study highlights importance of individualized, patient-centered therapies

Innovation in neuroscience drug discovery - eBook eBook

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Diabetes News and Research

Latest Diabetes News and Research

Innovation in neuroscience drug discovery - eBook eBook

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Newsletters you may be interested in